



Commissioner for Patents
PO Box 1450
Alexandria, VA 22313-1450

Robert Greene Starre
Edward J. Krasner
George A. Goldstein
David K.S. Cornwell
Robert W. Esposito
Tina M. Frazee Durkin
Michelle A. Cimbala
Michael B. Ray
Robert J. Sokohl
Ed C. Stoffle
Michael Q. Lee
Steven R. Ludwig
John H. Covert
Linda E. Green
Robert C. Millong
Donald J. Featherstone
Timothy J. Shea, Jr
Michael V. Messinger
Audith U. Ken

Patrick E. Garrett
Jeffrey T. Healey
Heidi L. Krausz
Eldora L. Ellison
Thomas C. Fiala
Albert J. *
Donald R. Banowitz
Peter A. Judkman
Teresa M. Medler
Jeffrey S. Silver
Kendrick P. Peterson
Vincent L. Capuano
Brian J. Deluono
Vigilant Beaman
Theodore A. Wood
Elizabeth J. Haines
Joseph J. Kozlowski
Frank R. Cunningham
Christine M. Uhler

Re: Lynn P. Guest
George S. Bandresser
Daniel A. Klein
Jason D. Esenberg
Michael D. Specht
Andrea M. Page
Tracy L. Miller
Jon E. Wright
Lorraine M. DeSantis
Ann E. Gitterman
Aric W. Ledford
Helene C. Carlson
Cynthia M. Boudreux
Timothy J. O'Leary
Gaby L. Longworth
Lori A. Gordon
Nicole D. Dzirar
Ted J. Benske
Laura A. Vogel

Michael J. Manasco
Bryan S. Wade
Aaron L. Schwartz
Michael G. Penn
Sharon L. Cambi
Wesley W. Jones
Matthew E. Kelley
Nicole R. Kramer

Michelle K. Heloubek
Simon J. Elitch
Julie A. Heider
Mita Mukherjee
Scott M. Woodhouse
Christopher J. Walsh
Liliana Di Heba-Baron
Peter A. Saccani
Jeffrey Mills

Registered Patent Agents*

Karen R. Markowicz

Nancy J. Leith

Matthew J. Dowd

Karen M. L. Quach

Bryan L. Slatkin

Robert A. Schwartzman

Teresa A. Collela

Jeffrey A. Landman

Victoria S. Rutherford

Of Counsel

Kenneth C. Bass III

Evan R. Smith

Marvin C. Guthrie

*Admitted only in Maryland

†Admitted only in Virginia

**Practices Limited to

Federal Agencies

July 21, 2005

WRITER'S DIRECT NUMBER:

(202) 772-8619

INTERNET ADDRESS:

SHWARTZ@SKGF.COM

Mail Stop: Amendment

Re: U.S. Utility Patent Application
Appl. No. 10/826,909; Filed: April 19, 2004
For: **Methods of Treating Diseases Responsive to Induction of Apoptosis and Screening Assays**
Inventors: Kasibhatla *et al.*
Our Ref: 1735.0840002/RWE/ALS

Sir:

Applicants submit the following documents for appropriate action by the U.S. Patent and Trademark Office:

1. First Supplemental Information Disclosure Statement Under 37 C.F.R. § 1.97(b);
2. Two (2) pages of Form PTO/SB/08B citing sixteen (16) documents;
3. Copies of the sixteen (16) cited documents; and
4. One (1) return postcard.

It is respectfully requested that the attached postcard be stamped with the date of filing of these documents, and that it be returned to our courier. The U.S. Patent and Trademark Office is hereby authorized to charge any fee deficiency, or credit any overpayment, to our Deposit Account No. 19-0036.

Respectfully submitted,

STERNE, KESSLER, GOLDSTEIN & FOX P.L.L.C.

Aaron L. Schwartz
Attorney for Applicants
Registration No. 48,181

RWE/ALS/law
Enclosures

423706_1.DOC



THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:

Kasibhatla *et al.*

Appl. No.: 10/826,909

Filed: April 19, 2004

For: **Methods of Treating Diseases
Responsive to Induction of Apoptosis
and Screening Assays**

Confirmation No.: 1721

Art Unit: 1614

Examiner: *To be assigned*

Atty. Docket: 1735.0840002/RWE/ALS

**First Supplemental Information Disclosure Statement
Under 37 C.F.R. § 1.97(b)**

Mail Stop Amendment

Commissioner for Patents
PO Box 1450
Alexandria, VA 22313-1450

Sir:

Listed on accompanying Form PTO/SB/08B are documents that may be considered material to the examination of this application, in compliance with the duty of disclosure requirements of 37 C.F.R. §§ 1.56, 1.97 and 1.98. Copies of documents **NPL1-NPL16** are submitted herewith.

This paper IDS is supplemental to an electronic IDS concurrently filed today. Any fee necessary for consideration of this Supplemental IDS has been authorized or otherwise submitted with the electronic IDS.

Applicants would also like to bring to the attention of the Examiner that, for the following documents, the day of publication could not be determined to the best of the Applicants' ability: **NPL10**, Abstract of Szekeres, T., *et al.*, "Benzamide riboside, a recent inhibitor of inosine 5'-monophosphate dehydrogenase induces transferrin receptors in cancer cells," *Curr. Med. Chem.* 9:759-764, Bentham Science Publishers Ltd. (April 2002).

With the exception of document NPL10, where the publication date of a listed document does not provide a month or date of publication, the year of publication of the listed document is sufficiently earlier or later than the effective U.S. filing date and any foreign priority date so that the month of publication is not in issue. Applicants have listed publication dates on the attached PTO/SB/08B based on information presently available to the undersigned. However, the listed publication dates should not be construed as an admission that the information was actually published on the date indicated.

Applicants reserve the right to establish the patentability of the claimed invention over any of the information provided herewith, and/or to prove that this information may not be prior art, and/or to prove that this information may not be enabling for the teachings purportedly offered.

This statement should not be construed as a representation that a search has been made, or that information more material to the examination of the present patent application does not exist. The Examiner is specifically requested not to rely solely on the material submitted herewith.


This Information Disclosure Statement is being filed before the mailing date of a first Office Action on the merits. No statement or fee is required.

It is respectfully requested that the Examiner initial and return a copy of the enclosed Form PTO/SB/08B, and indicate in the official file wrapper of this patent application that the documents have been considered.

The U.S. Patent and Trademark Office is hereby authorized to charge any fee deficiency, or credit any overpayment, to our Deposit Account No. 19-0036.

Respectfully submitted,

STERNE, KESSLER, GOLDSTEIN & FOX P.L.L.C.



Aaron L. Schwartz
Attorney for Applicants
Registration No. 48,181

Date: July 21, 2005

1100 New York Avenue, N.W.
Washington, D.C. 20005-3934
(202) 371-2600

408182_1.DOC



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

Complete if Known

**FIRST SUPPLEMENTAL
INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**
(Use as many sheets as necessary)

Sheet

1

of

2

Application Number	10/826,909
Filing Date	April 19, 2004
First Named Inventor	Kasibhatla, S.
Art Unit	1614
Examiner Name	<i>To be determined</i>
Attorney Docket Number	1735.0840002/RWE/ALS

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume number, publisher, city and/or country where published	T ²
	NPL1	Abstract of Bridge, J.A., et al., "Fusion of the ALK gene to the clathrin heavy chain gene, CLTC, in inflammatory myofibroblastic tumor," <i>Am. J. Pathol.</i> 159:411-415, The American Society for Investigative Pathology (2001)	
	NPL2	Abstract of Geminard, C., et al., "Reticulocyte maturation: mitoptosis and exosome release," <i>Biocell</i> 26:205-215, Instituto de Histología y Embriología (August 2002)	
	NPL3	Abstract of Hayashida-Hibino, S., et al., "The effect of TGF-beta1 on differential gene expression profiles in human corneal epithelium studied by cDNA expression array," <i>Invest. Ophthalmol. Vis. Sci.</i> 42:1691-1697, The Association for Research in Vision and Ophthalmology (2001)	
	NPL4	Abstract of Kalivendi, S.V., et al., "1-Methyl-4-phenylpyridinium (MPP+)-induced apoptosis and mitochondrial oxidant generation: role of transferrin-receptor-dependent iron and hydrogen peroxide," <i>Biochem. J.</i> 371:151-164, American Chemical Society (April 1, 2003)	
	NPL5	Abstract of Kedra, D., et al., "Characterization of a second human clathrin heavy chain polypeptide gene (CLH-22) from chromosome 22q11," <i>Hum. Mol. Genet.</i> 5:625-631, Oxford University Press (1996)	
	NPL6	Abstract of Lesnikov, V., et al., "Pro-apoptotic effects of transferrin and transferrin-derived glycans on hematopoietic cells and lymphocytes," <i>Exp. Hematol.</i> 29:477-489, International Society for Experimental Hematology and Elsevier Science, Inc. (2001)	
	NPL7	Abstract of Matsushima, T., et al., "Receptor binding cancer antigen expressed on SiSo cells, a novel regulator of apoptosis of erythroid progenitor cells," <i>Blood</i> 98:313-321, American Society of Hematology (2001)	
	NPL8	Abstract of Prescott, JL and Tindall, D.J., "Clathrin gene expression is androgen regulated in the prostate," <i>Endocrinology</i> 139:2111-2119, The Endocrine Society (1998)	
	NPL9	Abstract of Pushkareva, M.Y., et al., "Increased cell-surface receptor expression on U-937 cells induced by 1-O-octadecyl-2-O-methyl-sn-glycero-3-phosphocholine," <i>Cancer Immunol. Immunother.</i> 48:569-578, Springer-Verlag GmbH (2000)	
	NPL10	Abstract of Szekeres, T., et al., "Benzamide riboside, a recent inhibitor of inosine 5'-monophosphate dehydrogenase induces transferrin receptors in cancer cells," <i>Curr. Med. Chem.</i> 9:759-764, Bentham Science Publishers Ltd. (April 2002)	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional). ²Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO				Complete if Known	
FIRST SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)				Application Number	10/826,909
				Filing Date	April 19, 2004
				First Named Inventor	Kasibhatla, S.
				Art Unit	1614
				Examiner Name	To be determined
Sheet		2	of	2	Attorney Docket Number
NON PATENT LITERATURE DOCUMENTS					

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume number, publisher, city and/or country where published	T ²
	NPL11	Abstract of Tampo, Y., et al., "Oxidative stress-induced iron signaling is responsible for peroxide-dependent oxidation of dichlorodihydrofluorescein in endothelial cells: role of transferrin receptor-dependent iron uptake in apoptosis." <i>Circ. Res.</i> 92:56-63, Lippincott Williams & Wilkins (January 2003)	
	NPL12	Abstract of Thompson, K., et al., "Mouse brains deficient in H-ferritin have normal iron concentration but a protein profile of iron deficiency and increased evidence of oxidative stress." <i>J. Neurosci. Res.</i> 71:46-63, John Wiley & Sons, Inc. (January 2003)	
	NPL13	Abstract of Tournol, C., et al., "Further demonstration of the diversity of chromosomal changes involving 2p23 in ALK-positive lymphoma: 2 cases expressing ALK kinase fused to CLTC (clathrin chain polypeptide-like)." <i>Blood</i> 95:3204-3207, American Society of Hematology (2000)	
	NPL14	Abstract of Vaughan, A.T., et al., "The in vivo fate of a 211At labelled monoclonal antibody with known specificity in a murine system," <i>Int. J. Radiat. Oncol. Biol. Phys.</i> 8:1943-1946, Elsevier Inc. (1982)	
	NPL15	Abstract of Yen, C.F., et al., "Regulation of low-density lipoprotein receptors and assessment of their functional role in Burkitt's lymphoma cells," <i>Biochim. Biophys. Acta.</i> 1257:47-57, Elsevier B.V. (1995)	
	NPL16	Abstract of Trowbridge, I.S., et al., "Structure-Function Analysis of the Human Transferrin Receptor: Effects of Anti-Receptor Monoclonal Antibodies on Tumor Growth." <i>Curr. Stud. Hematol. Blood Trans.</i> 58:139-147, Karger (1991)	

Examiner Signature	Date Considered
--------------------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional). ²Applicant is to place a check mark here if English language Translation is attached.
This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.